Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

(2014) Jeffrey L. Lennox et al.   ANNALS OF INTERNAL MEDICINE

Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance?

(2014) Naishi Li et al.   ATHEROSCLEROSIS

Comparison of Body Composition Changes Between Atazanavir/Ritonavir and Lopinavir/Ritonavir Each in Combination with Tenofovir/Emtricitabine in Antiretroviral-Naïve Patients with HIV-1 Infection

(2014) Graeme J. Moyle et al.   CLINICAL DRUG INVESTIGATION

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

(2014) E Martinez et al.   HIV MEDICINE

Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study

(2014) M. Saumoy et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

(2013) Eric S. Daar   ANNALS OF INTERNAL MEDICINE

HIV-Associated Lipodystrophy: Impact of Antiretroviral Therapy

(2013) Giovanni Guaraldi et al.   DRUGS

Body Fat Distribution and Insulin Resistance

(2013) Pavankumar Patel et al.   Nutrients

Clinical Significance of Hyperbilirubinemia Among HIV-1–Infected Patients Treated with Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study

(2012) Cheryl McDonald et al.   AIDS PATIENT CARE AND STDS

Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 Weeks

(2012) Judith A. Aberg et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity

(2012) Graeme J Moyle et al.   ANTIVIRAL THERAPY

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

(2012) Edwin DeJesus et al.   LANCET

Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation

(2011) Marta Boffito et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes

(2011) Emilie Capel et al.   ANTIVIRAL THERAPY

Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s

(2011) G. A. McComsey et al.   CLINICAL INFECTIOUS DISEASES

Preferential Fat Deposition in SubcutaneousVersusVisceral Depots Is Associated with Insulin Sensitivity

(2011) Tracey McLaughlin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Drug resistance in HIV-1

(2011) Daniel R Kuritzkes   Current Opinion in Virology

Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults

(2010) Katherine Samaras et al.   AIDS

Impact of Switching from Lopinavir/Ritonavir to Atazanavir/Ritonavir on Body Fat Redistribution in Virologically Suppressed HIV-Infected Adults

(2010) Elena Ferrer et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

The Bilirubin-Increasing Drug Atazanavir Improves Endothelial Function in Patients With Type 2 Diabetes Mellitus

(2010) Douwe Dekker et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Human Immunodeficiency Virus Treatment–Induced Adipose Tissue Pathology and Lipoatrophy: Prevalence and Metabolic Consequences

(2010) Emma Hammond et al.   CLINICAL INFECTIOUS DISEASES

Boosting Dose Ritonavir Does Not Alter Peripheral Insulin Sensitivity in Healthy HIV-Seronegative Volunteers

(2010) Steven A Taylor et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials

(2010) David Moher et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

(2009) Roberto Ortiz et al.   AIDS

Abdominal Subcutaneous Adipose Tissue: A Protective Fat Depot?

(2009) S. A. Porter et al.   DIABETES CARE

Clinical pharmacology, efficacy and safety of atazanavir: a review

(2009) Danièle Bentué-Ferrer et al.   Expert Opinion on Drug Metabolism & Toxicology

Effects of ritonavir-boosted darunavirvs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers

(2009) F Tomaka et al.   HIV MEDICINE

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

(2008) Jean-Michel Molina et al.   LANCET